

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **The United Laboratories International Holdings Limited**

**聯邦制藥國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 3933)

### **UPDATED INFORMATION OF THE GROUP'S PRODUCTS**

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that on 12 July 2021, the insulin aspart injection and insulin aspart 30 injection that applied by Zhuhai United Laboratories Co., Ltd. (珠海聯邦制藥股份有限公司), a wholly-owned subsidiary of the Company, had passed the drug registration approval of National Medical Products Administration. Both of the approved insulin aspart injection and insulin aspart 30 injection include two specifications, being 3ml: 300U (refilled pen-type) and 3ml: 300U (disposable pen-type) with the drug approval numbers of S20210027, S20210028, S20210029 and S20210030 respectively.

Insulin aspart is a fast-acting insulin analogue for the diabetes treatment, and it can be administered by subcutaneously injection and insulin pump infusion. Compared with soluble human insulin, insulin aspart is characterized by both rapid onset of action and higher safety, and is able to improving postprandial glucose excursions significantly. It is a relatively important mealtime insulin in the diabetes treatment.

Insulin aspart 30 is a premixed insulin analogue consisting of 30% soluble insulin aspart and 70% protamine insulin aspart. It is characterized by rapid onset of action, which can better control postprandial glucose excursions and lower risk of hypoglycemia. It has a significant advantage in improving patient compliance.

The Company will continue to be devoted to the research and development of new products as well as enriching the product pipeline of diabetic drugs, and enhance its competitiveness and innovation in the biopharmaceutical industry, which is expected to create more benefits for the Company and its shareholders.

By Order of the Board  
**The United Laboratories International Holdings Limited**  
**Tsoi Hoi Shan**  
*Chairman*

Hong Kong, 15 July 2021

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.